In a significant blow to Pacira Pharmaceuticals and Pacira BioSciences, Judge Madeline Cox Arleo of the U.S. District Court for New Jersey entered final judgment on August 27, 2024, in favor of defendants Evenus Pharmaceuticals Laboratories, Jiangsu Hengrui Pharmaceuticals, and Fresenius Kabi USA. The court invalidated claim 7 of U.S. Patent No. 11,033,495 — the patent protecting EXPAREL®, Pacira’s bupivacaine liposome injectable suspension — finding it both anticipated by prior art and obvious. The case, filed November 8, 2021 and resolved after nearly three years of litigation, proceeded through a full trial before reaching this landmark ruling under Case No. 2:21-cv-19829.

This outcome carries substantial implications for pharmaceutical IP strategy, particularly for liposomal drug formulation patents and ANDA-related litigation. The ruling signals that even commercially successful drug delivery patents face heightened invalidity scrutiny when defendants mount coordinated challenges backed by strong prior art. IP professionals at branded pharmaceutical companies, generic manufacturers contemplating market entry, and R&D teams developing next-generation liposomal formulations should closely study this decision’s reasoning on anticipation and obviousness grounds.

Case Overview

The Parties

The Patent at Issue

U.S. Patent No. 11,033,495 (Application No. US17/156400) covers a specific formulation of bupivacaine liposome injectable suspension — a long-acting local anesthetic encapsulated in liposomal particles designed to provide extended post-surgical pain relief. The patent’s claim 7, which was the sole claim litigated to judgment, defines particular characteristics of the liposomal suspension that Pacira argued distinguished EXPAREL® from prior formulations. The commercial embodiment at issue is EXPAREL® (266 mg/20 mL, 13.3 mg/mL), a widely used non-opioid analgesic administered at the surgical site to reduce opioid dependency in post-operative care.

• • US11033495B1

Legal Representation

Plaintiff Counsel: Mccarter & English, LLP (lead: Cynthia Stencel Betz)
Defendant Counsel: Hill Wallack LLP (lead: Eric I. Abraham)

Litigation Timeline & Procedural History

The case was filed on November 8, 2021 in the U.S. District Court for the District of New Jersey — a venue with deep experience in Hatch-Waxman pharmaceutical patent litigation and one frequently chosen by branded drug companies for ANDA-related disputes given its specialized patent docket and judicial familiarity with complex drug formulation cases. The action proceeded as a first-instance district court matter before Chief Judge Madeline Cox Arleo, meaning the August 27, 2024 final judgment represents the trial-level ruling and the first substantive adjudication on the merits of the ‘495 patent’s validity. A consolidated companion case (No. 22-cv-00718) was joined, reflecting the multi-defendant coordination typical of Paragraph IV ANDA challenges.

The litigation spanned approximately 33 months from filing to final judgment — a duration consistent with fully contested pharmaceutical patent trials that proceed through fact discovery, expert discovery, claim construction, and a bench trial on validity. The case was resolved after a full trial on the merits rather than by motion or settlement, with the court issuing a substantive August 9, 2024 opinion (ECF No. 403) that formed the basis for the final judgment entered August 27, 2024. Notably, the court declined to reach defendants’ additional invalidity defenses of lack of enablement, non-infringement, and inequitable conduct, having found claim 7 invalid on anticipation and obviousness grounds alone — a procedurally efficient resolution that nonetheless leaves several subsidiary defenses available for reinstatement on remand if appealed.

The Verdict & Legal Analysis

Outcome

The District Court of New Jersey entered final judgment on August 27, 2024, entirely in favor of defendants Evenus Pharmaceuticals Laboratories, Jiangsu Hengrui Pharmaceuticals, and Fresenius Kabi USA. Claim 7 of U.S. Patent No. 11,033,495 was held invalid as both anticipated and obvious, and defendants’ counterclaims for declaratory judgment of invalidity were granted on the same grounds. No damages or injunctive relief were awarded to plaintiffs; defendants’ counterclaims for non-infringement and unenforceability were dismissed without prejudice as moot, subject to reinstatement on remand, and the court expressly preserved defendants’ rights to seek attorneys’ fees and costs under 35 U.S.C. § 285 within 30 days of final appellate disposition.

Verdict Cause Analysis

The court’s ruling rests on two independent and legally sufficient grounds of invalidity — anticipation and obviousness — each of which alone would have defeated the ‘495 patent’s claim 7.

• Claim 7 of U.S. Patent No. 11,033,495 was found anticipated, meaning that a single prior art reference disclosed every element of the claimed bupivacaine liposome formulation, negating novelty under 35 U.S.C. § 102.
• Claim 7 was independently found obvious under 35 U.S.C. § 103, indicating the court determined that the claimed formulation would have been readily apparent to a person of ordinary skill in pharmaceutical formulation arts at the relevant priority date.
• The court expressly reserved judgment on defendants’ additional invalidity defenses of lack of enablement and inequitable conduct, as well as the non-infringement defense, rendering those issues moot but preservable on appeal — a procedural posture that limits the precedential scope of this ruling to the anticipation and obviousness findings.
• Defendants’ preserved right to seek attorneys’ fees under 35 U.S.C. § 285 signals the court left open the possibility of an ‘exceptional case’ finding, which could result in a significant fee award against Pacira if no appeal is filed or if the appellate court affirms.

Legal Significance

1. This ruling reinforces that commercially successful drug delivery patents — even for blockbuster products like EXPAREL® — are not immune from invalidity challenges when defendants coordinate a multi-party prior art assault at the district court level, signaling that commercial success alone is insufficient to overcome strong anticipation evidence.
2. The court’s decision to invalidate on both anticipation and obviousness simultaneously, while declining to reach enablement and inequitable conduct, is a judicially efficient approach that may encourage future defendants to lead with prior art-based invalidity arguments rather than conduct-based defenses in pharmaceutical ANDA litigation.
3. The preservation of defendants’ non-infringement and unenforceability counterclaims without prejudice — contingent on appellate remand — creates a litigation posture where Pacira faces compounding risk if it appeals, potentially exposing the ‘495 patent to a broader invalidity and unenforceability record on remand.

Strategic Takeaways

For Patent Attorneys:

• When prosecuting liposomal drug formulation patents, conduct exhaustive prior art searches before claim drafting and ensure claim 7-level dependent claims introduce structurally distinct and measurable limitations that cannot be read onto earlier academic or regulatory prior art describing similar bupivacaine suspensions.
• The dual anticipation-and-obviousness holding in this case demonstrates that litigants should prepare independent invalidity theories at trial rather than relying on a single theory — and conversely, patent holders should be prepared to rebut both simultaneously with robust secondary considerations evidence including commercial success, long-felt need, and industry praise.
• Counsel representing branded pharmaceutical companies in ANDA litigation should proactively audit dependent claims of their formulation patents for vulnerability to anticipation by prior regulatory submissions, academic literature, or earlier formulation patents that may describe similar particle size, drug loading, or excipient profiles.
• The preserved § 285 fee motion window creates post-judgment leverage for defendants — plaintiff counsel should factor the risk of an exceptional case fee award into any cost-benefit analysis before filing a notice of appeal, particularly given the complete defense verdict on the merits.

For IP Professionals:

• Pharmaceutical IP teams holding liposomal formulation patents should immediately audit their portfolio for claims susceptible to anticipation by pre-filing regulatory or scientific literature, and consider whether continuation applications could recapture patentable subject matter with claim sets more clearly differentiated from the prior art landscape.
• In-house teams at generic manufacturers should monitor any appeal Pacira files from this judgment, as an appellate reversal on anticipation or obviousness could reinstate the full suite of defendants’ moot counterclaims — including non-infringement and inequitable conduct — creating a different risk calculus for ANDA approval timing decisions.

For R&D Teams:

• R&D teams developing bupivacaine or other liposomal local anesthetic formulations should treat the invalidation of claim 7 of US11033495B1 as a potential freedom-to-operate signal, but must conduct formal FTO analysis given that related patents in the Pacira portfolio and any pending appeals could still restrict commercialization of competing products.
• Product teams at generic pharmaceutical companies working on bupivacaine liposome injectable suspension formulations should document their development timeline and technical differentiation from EXPAREL® to build a contemporaneous record supporting both non-infringement and design-around arguments in the event Pacira asserts related patents in future litigation.